Investors Alert: Class Action Lawsuit Against Intellia Therapeutics
Pomerantz LLP has announced the filing of a class action lawsuit targeting Intellia Therapeutics, Inc (NASDAQ: NTLA). Investors are encouraged to reach out to the firm for more information regarding the lawsuit.
Details About the Class Action Lawsuit
The lawsuit primarily concerns allegations that Intellia and some of its executives may have been involved in securities fraud and other illegal business activities. Investors who purchased or acquired shares of Intellia during the defined Class Period should be aware of their rights and the available options.
Deadline for Lead Plaintiff Appointment
The deadline to request appointment as Lead Plaintiff for the class is approaching. Investors have until mid-April to file their applications. Various resources are provided to facilitate participation in this significant case.
Recent Company Developments
Intellia made headlines earlier this year with the dissemination of its strategic priorities and significant milestones for the upcoming year. The firm announced its focus on pivotal drug candidates, NTLA-2002 and nex-z, while discontinuing its development of NTLA-3001. This decision led to the company deciding to reduce its workforce by approximately 27% as part of a restructuring plan.
Financial Implications of Restructuring
The restructuring will incur an estimated charge of around $8 million within the first quarter. Additionally, Intellia revealed changes in leadership, including the retirement of its Chief Scientific Officer, Laura Sepp-Lorenzino, Ph.D. This wave of announcements had a marked impact on Intellia’s stock performance.
Impact on Stock Performance
In response to the company’s announcements, Intellia's stock price saw a notable decline. On January 10, it fell by $1.82, marking a 15.14% decrease to close at $10.20. This decline indicates investor reaction to upcoming changes as well as overall market sentiment regarding the company's directions.
About Pomerantz LLP
Established by Abraham L. Pomerantz, Pomerantz LLP is recognized widely as a reputable firm specializing in corporate, securities, and antitrust class litigation. Their expertise has evolved significantly over more than 85 years, continuing to advocate for victims of securities fraud and corporate misconduct. The firm has successfully recovered numerous multimillion-dollar damages awards for class members, reflecting their commitment to protect investor rights.
Frequently Asked Questions
What is the main focus of the class action lawsuit?
The lawsuit centers on allegations of securities fraud and unlawful business practices by Intellia Therapeutics and its executives.
When is the deadline to participate in the class action?
Investors must apply to be appointed as Lead Plaintiff by mid-April.
What recent changes has Intellia announced?
Intellia announced its strategic focus on drug candidates NTLA-2002 and nex-z and the discontinuation of NTLA-3001.
What impact did the recent announcements have on Intellia's stock?
Following the announcements, Intellia’s stock price dropped significantly by 15.14%.
Who can I contact for more information about the lawsuit?
Investors seeking more information can contact Danielle Peyton at Pomerantz LLP via phone or email.
